Verification of the impact on sequential therapy Of romosozumab according to the administration period of teriparatide

Verification of the impact on sequential therapy Of romosozumab according to the administration period of teriparatide - Verification of the impact on sequential therapy Of romosozumab according to the administration period of teriparatide

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000036854

Enrollment

Registered

2019-05-27

Start date

2019-05-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

osteoporosis

Interventions

Teriparatide less than 6 months, lomosozumab 12 months group Teriparatide 6 months or more and less than 12 months group Teriparatide 12 to 24 months administration group group

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1:All osteoporosis patients over 20 years old or older (but does not correspond to the following exclusion criteria) 2:Patients who agree with this study

Exclusion criteria

Exclusion criteria: 1:Patients who are allergic to romosozumab or teriparatide or eldecalcidol 2:Pregnant or breast-feeding patients 3:Patients considered to be at high risk of developing osteosarcoma 4:Patients with primary malignant or metastatic bone tumors 5:Patients with metabolic bone disease other than osteoporosis 6:Patients with unexplained high ALP 7:Others, patients judged by the research director as inappropriate 8:Hypocalcemia (serum corrected calcium level less than 8.0mg/dL) 9:Severe renal failure (less than eGFR15)

Design outcomes

Primary

Measure	Time frame
Bone mineral density change up to 12 months before and every 6 months after treatment start	—

Secondary

Measure	Time frame
Occurrence of hypocalcemia Occurrence of other adverse events	—

Countries

Japan

Contacts

Public ContactYukio Nakamura

Shinshu University School of Medicine Dept. of Orthopaedic Surgery

yxn14@aol.jp0263372659

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026